 |
BioWorld-International-2008-10-29
Apitope Raises 10M to Push its MS Drug to Phase II Trial
Commission Approves €90M for 'Theranostics' Program
No Abstract
BioWorld International Correspondent
PARIS - The European Commission has given the go-ahead for France's Innovation and Small Business Promotion Agency (OSEO) to provide a grant of €89.5 million (US$112.2 million) for a medical research program being coordinated by Mérieux Alliance.
Biotie Acquiring Elbion in $30M Cash, Shares Deal
Biotie Therapies Oyj gained ownership of Elbion GmbH in a cash and shares deal valued at €24.4 million (US$30.4 million). (BioWorld International)
Apitope Raises €10M to Push its MS Drug to Phase II Trial
No Abstract
BioWorld International Correspondent
LONDON - Apitope Ltd. was forced to look beyond the UK to raise €10 million (US$12.5 million) from Belgian investors in its first formal venture capital funding round. The money will enable the company to carry out a Phase II proof-of-concept trial of its peptide-based immunotherapy for multiple sclerosis and to commercialize a diagnostic for identifying the disorder in its early stages.